- Home
- SRPT vs HUMAW Comparison
SRPT vs HUMAW Comparison
Compare SRPT & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRPT
- HUMAW
- Stock Information
- Founded
- SRPT 1980
- HUMAW 2004
- Country
- SRPT United States
- HUMAW United States
- Employees
- SRPT N/A
- HUMAW 220
- Industry
- SRPT Biotechnology: Pharmaceutical Preparations
- HUMAW Biotechnology: Pharmaceutical Preparations
- Sector
- SRPT Health Care
- HUMAW Health Care
- Exchange
- SRPT Nasdaq
- HUMAW Nasdaq
- Market Cap
- SRPT 1.7B
- HUMAW N/A
- IPO Year
- SRPT 1997
- HUMAW N/A
- Fundamental
- Price
- SRPT $19.08
- HUMAW $0.55
- Analyst Decision
- SRPT Buy
- HUMAW
- Analyst Count
- SRPT 25
- HUMAW 0
- Target Price
- SRPT $64.00
- HUMAW N/A
- AVG Volume (30 Days)
- SRPT 8.0M
- HUMAW 14.2K
- Earning Date
- SRPT 08-06-2025
- HUMAW 03-21-2025
- Dividend Yield
- SRPT N/A
- HUMAW N/A
- EPS Growth
- SRPT N/A
- HUMAW N/A
- EPS
- SRPT N/A
- HUMAW N/A
- Revenue
- SRPT $2,233,371,000.00
- HUMAW N/A
- Revenue This Year
- SRPT $26.87
- HUMAW N/A
- Revenue Next Year
- SRPT $3.15
- HUMAW N/A
- P/E Ratio
- SRPT N/A
- HUMAW N/A
- Revenue Growth
- SRPT 59.15
- HUMAW N/A
- 52 Week Low
- SRPT $16.88
- HUMAW $1.18
- 52 Week High
- SRPT $154.90
- HUMAW $1.34
- Technical
- Relative Strength Index (RSI)
- SRPT 29.98
- HUMAW N/A
- Support Level
- SRPT $17.31
- HUMAW N/A
- Resistance Level
- SRPT $18.64
- HUMAW N/A
- Average True Range (ATR)
- SRPT 1.10
- HUMAW 0.00
- MACD
- SRPT 0.70
- HUMAW 0.00
- Stochastic Oscillator
- SRPT 44.66
- HUMAW 0.00
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.